Benet-Pages 2025 BRCA1/BRCA2 VUS reclassification study
Published-study grouping of the catalogued evaluation protocols. This grouping does not claim an executable suite, full-paper extraction or independent clinical validation.
Overview
Published-study grouping of the catalogued evaluation protocols. This grouping does not claim an executable suite, full-paper extraction or independent clinical validation.
Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.
2 recorded evaluations, 4 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.
Results
Results are available, but no reviewed comparison panel is linked in this release.
All evaluations
2 evaluations · 4 results. Different protocols are not a single leaderboard.
Filter evaluations
Applied filters: All linked evaluations
Source checking is not independent reproduction. Release 2026-10-06-fea06f63ac0e.
Methods and evaluation design
Procedure, tasks and evaluated configurations
Evaluation design
Benchmarks bring together tasks and protocols. A task describes the biological question; a protocol defines a particular test.
Protocols
These source-backed links do not make different protocols or scores interchangeable.
Baseline coverage
Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.
0 of 4 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.
Baseline status by linked protocol
- Benet-Pages BRCA1/BRCA2 VUS reclassification: ACMG/AMP + SVI step (t2) · 0/2 roles measured
- Benet-Pages BRCA1/BRCA2 VUS reclassification: ENIGMA VCEP step (t3) · 0/2 roles measured
Protocol coverage CSV · Model evaluation matrix · Source table · Release and checksums
Coverage is derived from release 2026-10-06-fea06f63ac0e. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.
Run this benchmark
Choose a concrete protocol before running an evaluation. Its inputs, split and scoring rules determine which results can be compared.
Run instructions
No runnable recipe has been reviewed for this benchmark. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.
Strengths, limitations and unresolved questions
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
0 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|
No evidence rows match these filters. Choose another scope or clear the search.
Sources and history
View linked audit checks and correction history
Release 2026-10-06-fea06f63ac0e · Record review: source checked
1 source records and release history
- Reclassification of VUS in BRCA1 and BRCA2 using the new BRCA1/BRCA2 ENIGMA track set demonstrates the superiority of ClinGen ENIGMA Expert Panel specifications over the standard ACMG/AMP classification system · Original source · 2025 published article (Genetics in Medicine Open); ENIGMA BRCA1/BRCA2 VCEP specification v1.1.0 applied
Technical metadata and extraction receipts
Stable ID: uc-clinical-20261005-benet-pages-benchmark
- areas
- dna-genomes
- contexts
- clinical_research
- entity level
- suite
- grouping type
- published_study_evaluations
- executable suite
- false
- source locator
- Results, "Reclassification of variants using the ACMG/AMP classification system with SVI recommendations and new data (ACMG/AMP + SVI)"; Results, "Reclassification of variants using the ENIGMA specifications (ENIGMA VCEP)"
- review
- method: automated_source_review; reviewer: Claude Sonnet clinical coverage worker (research-evidence intake); date: 2026-10-05; note: Transcription from inspected primary source. No execution, independent replication or human scientific review.; source id: uc-clinical-20261005-source-benet-pages